Neuro

Ashvattha Therapeutics Announces Poster Presentation of Preclinical Data on Hydroxyl Dendrimer-Based PET Tracer [18F]OP-801 at the 2022 Alzheimer's Association International Conference (AAIC)

Retrieved on: 
Monday, July 18, 2022
Traffic barrier, San Diego Convention Center, Patient, Johns Hopkins University, Neurodegeneration, Neurology, Inflammation, ALS, Therapy, Stanford University, GLOBE, Technology, Ashvattha, Poster, Conference, DME, Brain, AMD, HDS, Neuroinflammation, KDA, Alzheimer's disease, Neuro, AAIC, CA, PET, Spinal cord, TSPO, HDT, Amyotrophic lateral sclerosis, Diabetic retinopathy, Medical imaging, Ophthalmology

REDWOOD CITY, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced a poster presentation of preclinical data on the sensitivity of its hydroxyl dendrimer-based PET tracer, [18F]OP-801, in comparison to translocator protein 18 kDa [TSPO]-PET, using [18F]GE180 (TSPO-PET), an established PET imaging approach for the detection of neuroinflammation, in a mouse model of Alzheimer’s Disease. The data will be presented by scientific collaborators at Stanford University in a poster at the 2022 Alzheimer's Association International Conference (AAIC) taking place at the San Diego Convention Center in San Diego, CA, and online, July 31 – August 4, 2022.

Key Points: 
  • The data will be presented by scientific collaborators at Stanford University in a poster at the 2022 Alzheimer's Association International Conference (AAIC) taking place at the San Diego Convention Center in San Diego, CA, and online, July 31 August 4, 2022.
  • Poster presentation details can be found below:
    [18F]OP-801 is a hydroxyl dendrimer-based neuroimaging agent being developed as a companion biomarker and a pharmacodynamic tool for therapeutics to treat neuroinflammation due to neurodegenerative diseases including Alzheimers and amyotrophic lateral sclerosis (ALS).
  • Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in ophthalmology, neurology, inflammatory diseases and neuro-oncology.
  • HDs chemically conjugated to disease-modifying drugs create novel proprietary HD therapeutics (HDTs) selectively targeting reactive inflammatory cells in disease tissue with localized sustained effects.

BioAdaptives, Inc. Launching Next Generation Products for Natural Health Practitioners

Retrieved on: 
Thursday, July 14, 2022
Infection, Horse, Security (finance), U.S. Securities and Exchange Commission, Nutrient, Sleep, Animal, Cognition, Company, Food and Drug Administration, Neuro, Patient, OTC, Risk factor, Brain, COVID-19, Food, GLOBE, Private Securities Litigation Reform Act, Human, Fatigue, Dog, Health, Massage, Exercise, Memory, Medicine, Pharmaceutical industry

LAS VEGAS, NV, July 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioAdaptives, Inc. (OTCMkts:  BDPT) is launching an enhanced product line for holistic healthcare practitioners.  The next generation products are more advanced versions of proven existing nutraceuticals with changes to ingredients, dose and/or composition.  We will continue to offer our current consumer products to retail customers on-line:  PluriPain®, PrimiSleep™, PrimiLungs™ and PrimiCell™, plus a soon-to-be-launched nootropic, PluriMind.  For holistic healthcare practitioners, we will offer “Nu” branded products with enhanced functions in these same areas.

Key Points: 
  • The next generation products are more advanced versions of proven existing nutraceuticals with changes to ingredients, dose and/or composition.
  • We will continue to offer our current consumer products to retail customers on-line: PluriPain, PrimiSleep, PrimiLungs and PrimiCell, plus a soon-to-be-launched nootropic, PluriMind.
  • For holistic healthcare practitioners, we will offer Nu branded products with enhanced functions in these same areas.
  • These symptoms are challenging for patients and the professionals who want to help manage their clients health needs.

Wedge Teams Up with Elsa’s Touch to Help Cure Glioblastoma

Retrieved on: 
Tuesday, July 12, 2022
Technology, Disease, Student, Education, Program, Family, Brain, HR, Solution, Awareness, Somatosensory system, Glioblastoma, Neuro, Patient, Neuroscience, Society, Love, GLOBE, Pakistan Society of Neuro-Oncology, SNO, Research, Annual general meeting, Partnership, Medicine, Wedge

Dedicated to preserving the legacy of Elsa Jatwani, Elsas Touch works alongside Cure Glioblastoma , a Los Angeles-based 501c3 nonprofit public charity, to provide scholarships to students studying neuroscience and neuro-oncology.

Key Points: 
  • Dedicated to preserving the legacy of Elsa Jatwani, Elsas Touch works alongside Cure Glioblastoma , a Los Angeles-based 501c3 nonprofit public charity, to provide scholarships to students studying neuroscience and neuro-oncology.
  • Dylan Jatwani, one of Elsas sons, shared, In August 2018, my mom was diagnosed with glioblastoma brain cancer, an aggressive form with no cure.
  • Cure Glioblastoma co-founder and president, Shawn Carbonell, M.D., Ph.D., said, We founded Cure Glioblastoma to help todays patients and invest in tomorrows solutions.
  • We are honored to be part of what Elsas Touch and Cure Glioblastoma are doing.

Radius Announces First Patient Randomized in the RAD011 Pivotal Trial for Prader-Willi Syndrome

Retrieved on: 
Thursday, July 7, 2022
Fracture, FDA, Neuro, Annual report, Patient, Caregiver, Achievement, Trial of the century, GLOBE, Prader–Willi syndrome, Man, COVID-19, Program, Angelman syndrome, RAD1901, Goal, U.S. Securities and Exchange Commission, Awareness, Fast Track, Food, Woman, Risk, Clinical trial, Private Securities Litigation Reform Act, PWS, SEC, Neuropsychiatric Disease and Treatment, Osteoporosis, Spasm, Polyphagia, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Security (finance), Pharmaceutical industry, Radius

Currently, 9 US sites are activated for screening and patient recruitment will continue across the US and globally as non-US sites are activated.

Key Points: 
  • Currently, 9 US sites are activated for screening and patient recruitment will continue across the US and globally as non-US sites are activated.
  • RAD011 has Orphan Drug Designation and has been granted Fast Track by the U.S. Food and Drug Administration (FDA).
  • Radius has initiated a seamless pivotal Phase 2/3 study for patients with Prader-Willi Syndrome.
  • These forward-looking statements should not be relied upon as representing Radius views as of any date subsequent to the date of this press release.

BetterLife Secures Additional Mitacs Funding in Collaboration with Carleton University Research Team for BETR-001 Preclinical Depression Studies

Retrieved on: 
Wednesday, July 6, 2022
Department, Headache, Neuro, Anxiety, Research, University, Investigational New Drug, Physical disorder, GLOBE, Lists of diseases, Carleton University, COVID-19, Hallucination, CSE, Post-traumatic stress disorder, Degenerative disease, Depression, Private sector, Mitacs, LSD, Principal, IND, Disorder, Organization, MOA, Lysergic acid diethylamide, Patent, Mental health, Postdoctoral researcher, Pharmaceutical industry

"BETR-001 is a potential novel therapy to treat debilitating psychiatric disorders with high unmet need, such as treatment-resistant severe depression and cluster headaches.

Key Points: 
  • "BETR-001 is a potential novel therapy to treat debilitating psychiatric disorders with high unmet need, such as treatment-resistant severe depression and cluster headaches.
  • BETR-002, which is in preclinical and IND-enabling studies, is based on honokiol, the active anxiolytic ingredient of magnolia bark.
  • Carleton Neuroscience has an international reputation for research on stress and its effects on brain functioning and mental health.
  • Mitacs is a national, not-for-profit organization that has designed and delivered research and training programs in Canada for 20 years.

Fulcrum Therapeutics Enrolls First Patient in Pivotal Global Phase 3 Clinical Trial of Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)

Retrieved on: 
Tuesday, July 5, 2022
Patient, European Medicines Agency, Losmapimod, MFI, Caregiver, Research, American Academy, Muscle weakness, Muscle, GLOBE, 3D, Securities and Exchange Commission (Philippines), EMA, Fulcrum, IND, Muscular dystrophy, Quality of life, FSHD, Scapula, Therapy, Security (finance), FDA, Hobby, Neuro, Hemoglobinopathy, GSK, Sickle cell disease, Chronic pain, Facioscapulohumeral muscular dystrophy, Population, Fast track (FDA), PGIC, Thalassemia, Instagram, Twitter, Facial expression, Motion, LinkedIn, CEO, Fetal hemoglobin, Face, RWS, Private Securities Litigation Reform Act, Nasdaq, Ascending limb of loop of Henle, Leadership, Review, DUX4, Journal, Quality, HIV disease progression rates, Gene expression, Abdomen, Disease, Orphan, Safety, MAPK, Pharmaceutical industry, Dentistry, Medical imaging, REACH, Facebook

CAMBRIDGE, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the first patient has been dosed in REACH, a Phase 3 clinical trial designed to evaluate the safety and efficacy of losmapimod for the treatment of FSHD. The randomized, double-blind, placebo-controlled, multi-national Phase 3 trial will enroll approximately 230 adults at over 30 sites in North America and Europe. The pivotal trial is designed to support the U.S. FDA and European Medicines Agency (EMA) regulatory applications of lospmapimod for the treatment of FSHD. If approved, losmapimod would be the first and only therapy for the disease.

Key Points: 
  • The randomized, double-blind, placebo-controlled, multi-national Phase 3 trial will enroll approximately 230 adults at over 30 sites in North America and Europe.
  • The pivotal trial is designed to support the U.S. FDA and European Medicines Agency (EMA) regulatory applications of lospmapimod for the treatment of FSHD.
  • Results from Fulcrums Phase 2 clinical trial, ReDUX4, demonstrated that losmapimod was superior to placebo across a number of clinically relevant endpoints.
  • However, while Fulcrum may elect to update these forward-looking statements at some point in the future, Fulcrum specifically disclaims any obligation to do so.

ERC Announces Publication of Positive Efficacy Data with Sitoiganap in Patients with Recurrent Glioblastoma

Retrieved on: 
Thursday, June 30, 2022
Cell, Frontiers, Neuro, Patient, ERC, CEO, Glioblastoma, Brain, GLOBE, Gliosarcoma, Cancer, Disease, Mass flow (life sciences), Prognosis, Epitopoietic Research Corporation, Neoplasm, Toxicity, Doctor of Philosophy, Survival, Quality of life, Immunotherapy, Safety, Epitope, Recurrence, MD, Hope, Observation, Pharmaceutical industry, Medical imaging, Medicine

The authors reported striking efficacy and safety of a therapeutic vaccine SITOIGANAP administered to 21 patients with recurrent glioblastoma (rGBM).

Key Points: 
  • The authors reported striking efficacy and safety of a therapeutic vaccine SITOIGANAP administered to 21 patients with recurrent glioblastoma (rGBM).
  • Glioblastoma has a dismal prognosis with half of rGBM patients dying within 8 months of recurrence of the disease.
  • Data presented by the authors show that treatment with Sitoiganap (also called Gliovac or ERC1671) more than doubles median overall survival to 19.6 months.
  • Sitoiganap is for patients suffering from a grade IV glioma (glioblastoma and gliosarcoma) when all other traditional treatments have failed.

MellingMedical Adds Fehling Surgical Products to Expanding Medical/Surgical Portfolio

Retrieved on: 
Wednesday, June 29, 2022
Department, Neuro, Surgeon, Patient, Manchester VA Medical Center, CEO, IHS, HHS, Percussion section, Health, Medicine, Hermann von Fehling, Equipment, Center, Veteran, Centers for Disease Control and Prevention timeline, CVE, Urology, SDVOSB, Indian Health Service, United States Department of Veterans Affairs, Multimedia, CDC, Hospital, Optometry, Ophthalmology

ALEXANDRIA, Va., June 29, 2022 /PRNewswire/ -- As part of an enduring commitment to equipping surgeons in the federal healthcare system with the best tools possible, MellingMedical is pleased to provide access to the full suite offered by Fehling Surgical Instruments, Inc. As a CVE-Verified Service-Disabled Veteran-Owned Small Business (SDVOSB), MellingMedical is especially proud of the positive impact this can have on the care provided to America's veterans.

Key Points: 
  • MellingMedical and Fehling Instruments will help countless patients across the federal healthcare system.
  • Based in Kennesaw, Georgia, Fehling Surgical Instruments, Inc. is the exclusive distributor of German-manufactured Fehling products in the United States and Canada.
  • "Whether they choose one of our premium surgical instruments or single-use products, we are honored to play a role in the delivery of quality care."
  • Fehling Instruments is a traditional family-owned and family-run company with more than thirty years of experience in designing, manufacturing and distributing high-grade German surgical instruments and single-use products.

Calidi Biotherapeutics Announces Appointment of W.K. Alfred Yung, M.D., to its Medical Advisory Board

Retrieved on: 
Tuesday, June 28, 2022
Science, Biotechnology, Research, Oncology, General Health, Health, FDA, Clinical Trials, FDA, Neuro, Patient, Business, Securities Act of 1933, B cell, Precision medicine, MD Anderson Cancer Center, Register, Potyvirus, COVID-19, Failure, Sale, U.S. Securities and Exchange Commission, Prospectus, Suite, Glioblastoma, Form, PIPE, Risk, Cancer, Person, Proxy, Business architecture, Neuro-Oncology (journal), Patient safety, Name, Plan, SEC, Brain, Private Securities Litigation Reform Act, Safety, Neuro-oncology, Nature, Northwest Biotherapeutics, Security (finance), Pharmaceutical industry, Vaccine, Risk management, Edoc

Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company that is pioneering the development of stem cell-based delivery of oncolytic viruses, today announced the appointment of W.K.

Key Points: 
  • Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company that is pioneering the development of stem cell-based delivery of oncolytic viruses, today announced the appointment of W.K.
  • Alfred Yung, M.D., Professor, Neuro-Oncology at the MD Anderson Cancer Center, to its Medical Advisory Board.
  • Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology that is revolutionizing the effective delivery of oncolytic viruses for targeted therapy against difficult-to-treat cancers.
  • Calidi Biotherapeutics is advancing through the FDA approval process a potent allogeneic stem cell and oncolytic virus combination for use in multiple oncology indications.

Coya Therapeutics Announces Peer-Reviewed Publication of its First-in-Class Regulatory T Cell-derived Exosomes and their Therapeutic Potential in Neurodegeneration and Inflammation Related Diseases

Retrieved on: 
Thursday, June 23, 2022
Spinal cord, Immunology, Therapy, Animal, Inflammation, Technology, Amyotrophic lateral sclerosis, CEO, Exosome, Survival, Neuro, Degenerative disease, Disease, Protein, Seminal vesicles, CMO, IND, Coya, FTD, HIV disease progression rates, Patient, ALS, GLOBE, Pharmaceutical industry, Fibrosis, Scleroderma, Regulatory T cell

When administered into preclinical mouse models of disease, the Treg-derived exosomes demonstrated systemic and neurological anti-inflammatory function in an inflammatory mouse model of disease.

Key Points: 
  • When administered into preclinical mouse models of disease, the Treg-derived exosomes demonstrated systemic and neurological anti-inflammatory function in an inflammatory mouse model of disease.
  • Together, these data provide preclinical evidence supporting the exciting therapeutic potential of expanded Treg-derived exosomes to treat inflammation in human disease.
  • Howard Berman, Ph.D., CEO of Coya Therapeutics stated, Treg-derived exosomes represent the next generation of immunomodulatory therapeutics to treat inflammatory-related disorders.
  • Headquartered in Houston, TX, Coya Therapeutics, Inc. (Coya) is a clinical-stage biotechnology company developing first-in-class and best-in-class approaches utilizing Treg modifying therapeutics to target systemic and neuro inflammation.